RegeneRx Biopharmaceuticals EBIT

The latest EBIT for RGRX is $-1M as of September 2023. That compares with $-2.9M in the prior-year period — up 65.6% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside RegeneRx Biopharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, RGRX's EBIT moved from $-2.9M to $-1M — a 65.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in RegeneRx Biopharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, RGRX currently prints $-1M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at RegeneRx Biopharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-1M for RGRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting RGRX's EBIT ($-1M), review year-over-year change from $-2.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.